May 9 (UPI) -- A South Korean biotech company is likely to benefit greatly from the policy of the U.S. Food and Drug Administration , which is scheduled to retire animal testing. Organoid Science debuted on the Seoul bourse Friday, with its share price surging by 52.38% on Day 1. The firm focuses on lab-grown miniature organs, which can be used for clinical tests. In South Korea, share value is not permitted to rise more than 30% a day, except for newly listed stocks, which may rise up to three